Skip to main content
NCBI home page
Scientific Reports logoLink to Scientific Reports
. 2016 Jul 1;6:28044. doi: 10.1038/srep28044

Prognostic values of four Notch receptor mRNA expression in gastric cancer

Xiaoyu Wu 1,*, Wentao Liu 2,*, Ding Tang 3, Haijuan Xiao 4, Zhenfeng Wu 1, Che Chen 1, Xuequan Yao 1, Fukun Liu 1, Gang Li 5,a
PMCID: PMC4929462  PMID: 27363496

Abstract

Notch ligands and receptors are frequently deregulated in several human malignancies including gastric cancer. The activation of Notch signaling has been reported to contribute to gastric carcinogenesis and progression. However, the prognostic roles of individual Notch receptors in gastric cancer patients remain elusive. In the current study, we accessed the prognostic roles of four Notch receptors, Notch 1–4, in gastric cancer patients through “The Kaplan-Meier plotter” (KM plotter) database, in which updated gene expression data and survival information include a total of 876 gastric cancer patients. All four Notch receptors’ high mRNA expression was found to be correlated to worsen overall survival (OS) for all gastric cancer patients followed for 20 years. We further accessed the prognostic roles of individual Notch receptors in different clinicopathological features using Lauren classification, pathological grades, clinical grades, HER2 status and different choices of treatments of gastric cancer patients. These results indicate that there are critical prognostic values of the four Notch receptors in gastric cancer. This information will be useful for better understanding of the heterogeneity and complexity in the molecular biology of gastric cancer and to develop tools to more accurately predict their prognosis.

Gastric cancer is the second most common cause of cancer-related death, and 800,000 cancer-related deaths are caused by gastric cancer each year globally1 Despite the advances in early detection, radical cure operation, and multimodal therapeutic modalities, at diagnosis, gastric cancer remains difficult to cure and prognosis remains poor with a median overall survival of 12 months for advanced disease in Western countries2,3. About 40–60% patients with gastric cancer received radical operation will often have postoperative recurrence and metastasis4. Therefore, in order to improve the clinical outcome of gastric cancer patients, the identification of the molecular mechanism during the incidence and progression of gastric cancer, as well as identification of prognostic biomarkers and drug targets are still needed and will help to select patients with higher chances of gastric cancer recurrence and provide better prognosis and individualized treatments.

The Notch signaling pathway is one of key pathways constituting the stem cell signaling network and is a highly conserved system that regulates cell-fate decisions and the maintenance of stem cells5,6. DLL1, DLL3, DLL4, JAG1 and JAG2, typical Notch ligands, and four Notch receptors (Notch 1–4) are frequently deregulated in several human malignancies and have been found in breast, colon, cervical, head and neck, lung, pancreatic, prostate cancer, ovarian cancer, renal carcinoma, acute myeloid, Hodgkin and Large-cell lymphomas, as well as gastric cancer7,8,9,10,11,12. A number of studies have shown that the activation of Notch signaling plays a critical role in gastric cancer initiation, progression and cross-talks with other signaling pathways, contributing to the apoptosis inhibition, development, angiogenesis, metastasis and chemoresistance of gastric cancer7,13,14,15,16,17,18. However, the prognostic roles of individual Notch receptors, especially at the mRNA level in gastric cancer patients remains elusive. In the current study, we accessed the prognostic roles of four Notch receptors in human gastric cancer patients by the Kaplan-Meier plotter (KM plotter).

KM plotter generated data from Gene Expression Omnibus (GEO-www.ncbi.nlm.nih.gov/geo/) database. This database includes gene expression data and survival information from a total of 876 gastric cancer patients. KM plotter can be utilized for the analysis of individual genes with clinical results to relapse-free survival and total survival of the patients. So far, a number of genes have been identified and/or validated by KM plotter in lung cancer19,20,21,22, breast cancer22,23,24,25,26,27,28,29,30,31,32, and ovarian cancer22,33,34. In this study, we used KM plotter database and accessed the prognostic roles of individual Notch receptor mRNA expression in human gastric cancer patients.

Material and Methods

An online database35 (http://kmplot.com/analysis/) was used to determine the relevance of individual Notch receptor mRNA expression to the overall survival (OS). OS is the length of time from either the date of diagnosis or the start of treatment for a cancer patient, that patients diagnosed with the cancer are still alive. In a clinical trial, measuring the OS is one of important ways to see how well a new treatment works. Currently, they established breast cancer35, lung cancer19, ovarian cancer36 and gastric cancer data. All cancer patients in the database were identified from Cancer Biomedical Informatics Grid (caBIG, http://cabig.cancer.gov/, microarray samples are published in the caArray project), the Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and The Cancer Genome Atlas (TCGA, http://cancergenome.nih.gov) cancer datasets19. They collected clinical data including gender, perforation history, Lauren classification, differentiation, stage, HER2 status and treatment. The database was established using gene expression data and survival information of 876 gastric cancer patients downloaded from Gene Expression Omnibus (GEO). Briefly, four Notch sub-members (Notch1, Notch2, Notch3 and Notch4) were entered into the database (http://kmplot.com/analysis/index.php?p=service&cancer=gastric) to obtain Kaplan-Meier survival plots in which the number-at-risk is indicated below the main plot. Hazard ratio (HR) and 95% confidence intervals, as well as log rank P were calculated and displayed on the webpage. P value of <0.05 was considered to be statistically significant. HR is the ratio of the hazard rates corresponding to the conditions described by two levels of an explanatory variable in survival analysis.

Results

Mammals possess four different notch receptors, referred to as Notch1, Notch2, Notch3 and Notch4. All Notch receptors Kaplan-Meier survival information can be found in www.kmplot.com. We first accessed the prognostic value of Notch1 mRNA expression in www.kmplot.com. The desired Affymetrix IDs is valid: 218902_at (Notch1). Survival curves were plotted for gastric cancer patients (n = 876) (Fig. 1A), for intestinal type cancer patients (n = 320) (Fig. 1B), and for diffuse type cancer patients (n = 241) (Fig. 1C). Notch1′s high mRNA expression was found to be correlated to worsen OS for all gastric cancer patients followed for 20 years, HR 1.38 (1.16–1.64), p = 0.00022. Notch1 high mRNA expression was also found to be correlated to worsen OS in intestinal type cancer patients, HR 1.82 (1.25–2.64), p = 0.0014, but not in diffuse type cancer patients, HR 1.37 (0.96–1.94), p = 0.078.

Figure 1. Determination of prognostic value of Notch1 mRNA expression in www.kmplot.com. The desired Affymetrix IDs is valid: 218902_at (Notch1).

Figure 1

Open in a new tab

(A) Survival curves are plotted for all gastric cancer patients (n = n = 876). (B) Survival curves are plotted for intestinal type cancer patients (n = 320). (C) Survival curves are plotted for diffuse type cancer patients (n = 241).

We then accessed the prognostic value of Notch2 mRNA expression in www.kmplot.com. The desired Affymetrix IDs is valid: 210756_s_at (Notch2). Notch2′ high mRNA expression was found to be significantly correlated to worsen OS for all gastric cancer patients, HR 1.58 (1.31–1.89), p = 6.5e-07 (Fig. 2A), as well as in intestinal type cancer patients, HR 2.36 (1.72–3.25), p = 5.3e-08 (Fig. 2B), and in diffuse type cancer patients, HR 1.62 (1.15–2.28), p = 0.0051 (Fig. 2C).

Figure 2. Determination of prognostic value of Notch2 mRNA expression in www.kmplot.com.

Figure 2

Open in a new tab

The desired Affymetrix IDs is valid: 210756_s_at (Notch2). (A) Survival curves are plotted for all gastric cancer patients (n = n = 876). (B) Survival curves are plotted for intestinal type cancer patients (n = 320). (C) Survival curves are plotted for diffuse type cancer patients (n = 241).

Figure 3 showed the prognostic value of Notch3 mRNA expression in www.kmplot.com. The desired Affymetrix IDs is valid: 203237_at (Notch3). Notch3′ high mRNA expression was found to be significantly correlated to worsen OS for all gastric cancer patients, HR 1.6 (1.31–1.97), p = 5.3e-06 (Fig. 3A), as well as in intestinal type cancer patients, HR 2.03 (1.36–3.03), p = 0.00039 (Fig. 3B), and diffuse type cancer patients, HR 1.5 (1.06–2.11), p = 0.02 (Fig. 3C).

Figure 3. Determination of prognostic value of Notch3 mRNA expression in www.kmplot.com.

Figure 3

Open in a new tab

The desired Affymetrix IDs is valid: 203237_at (Notch3). (A) Survival curves are plotted for all gastric cancer patients (n = n = 876). (B) Survival curves are plotted for intestinal type cancer patients (n = 320). (C) Survival curves are plotted for diffuse type cancer patients (n = 241).

Figure 4 showed the prognostic value of Notch4 mRNA expression in www.kmplot.com. The desired Affymetrix IDs is valid: 205247_at (Notch4). Notch4′s high mRNA expression was also found to be significantly correlated to worsen OS for all gastric cancer patients, HR 1.98 (1.64–2.4), p = 9.3e-13 (Fig. 4A), intestinal type cancer patients, HR 2.47 (1.77–3.64), p = 4.6e-08 (Fig. 4B), and diffuse type cancer patients, HR 1.81 (1.18–2.76), p = 0.0054 (Fig. 4C).

Figure 4. Determination of prognostic value of Notch4 mRNA expression in www.kmplot.com.

Figure 4

Open in a new tab

The desired Affymetrix IDs is valid: 205247_at (Notch4). (A) Survival curves are plotted for all gastric cancer patients (n = n = 876). (B) Survival curves are plotted for intestinal type cancer patients (n = 320). (C) Survival curves are plotted for diffuse type cancer patients (n = 241).

For further access to the correlation of individual Notch receptors with other clinicopathological features, we accessed the correlation with gender (Table 1), pathological grades (Table 2), clinical grades (Table 3), HER2 status (Table 4) and different choices of treatments (Table 5) of gastric cancer patients. As from Table 1, all the individual Notch receptors did not show significant difference of prognosis in different gender positive gastric cancer patients. From Table 2, all the individual Notch receptors except Notch 2 were not significantly associated with pathological grades of gastric cancer patients. Notch 2′s high mRNA expression was associated with worsen OS in grade I gastric cancer patients, HR 10.5 (1.4–78.81), p = 0.0046. From Table 3, Notch 1′s high mRNA high expression was associated with worsen OS in grade II, HR 1.95 (1.04–3.64), p = 0.033 and grade III, HR 1.49 (1.07–2.06), p = 0.017. Notch 2′s high mRNA expression was associated with worsen OS in grade II, HR 2.26 (1.23–4.14), p = 0.0066 and grade III, HR 2.03 (1.46–2.82), p = 1.7e-05. Notch 3′s high mRNA expression was associated with worsen OS in grade III, HR 1.8 (1.26–2.57), p = 0.0011. Notch 4′s high mRNA expression was associated with worsen OS in grade I, HR 3.7 × 108 (0.0-inf), p = 0.0035, grade II, HR 2.32 (1.26–4.25), p = 0.0052 and grade III, HR 1.83 (1.31–2.54), p = 0.00028. From Table 4, all the individual Notch receptors except Notch 3 were significantly associated with worsen OS in either HER2 negative or HER2 positive gastric cancer patients. Notch 3′s high mRNA expression was only significantly associated with worsen OS in HER2 negative gastric cancer patients, HR 1.57 (1.22–2.01), p = 0.00043. From Table 5, Notch 1′s high mRNA expression was associated with worsen OS in surgery alone gastric cancer patients, HR 1.4 (1.02–1.93), p = 0.037; as well as 5-FU based adjuvant gastric cancer patients, HR 1.53 (1.07–2.19), p = 0.019. Notch 2′s high mRNA expression was only associated with better OS in 5-FU based adjuvant gastric cancer patients, HR 0.61 (0.43–0.87), p = 0.0059. Notch 3′s high mRNA expression was only associated with worsen OS in surgery alone gastric cancer patients, HR 1.42 (1.00–2.02), p = 0.048. Notch 4 s’ high mRNA expression was also only associated with worsen OS in surgery alone gastric cancer patients, HR 2.12 (1.48–3.03), p = 2.7e-05.

Table 1. Correlation of Notch receptor mRNA high expression with gender of gastric cancer patients.

Notch receptors Treatment Cases HR 95% CI P value
Notch1 Male 545 1.32 (1.06–1.63) 0.012
Female 236 1.73 (1.22–2.47) 0.0021
Notch2 Male 545 1.9 (1.51–2.38) 1.8e-08
Female 236 1.73 (1.12–2.67) 0.012
Notch3 Male 545 1.49 (1.16–1.92) 0.0019
Female 236 1.71 (1.13–2.59) 0.011
Notch4 Male 545 2.21 (1.74–2.8) 3e-15
Female 236 2.43 (1.47–4.01) 0.00032
Open in a new tab

Table 2. Correlation of Notch receptor mRNA high expression with pathological grades of gastric cancer patients.

Notch receptors Pathological grades Cases HR 95% CI P value
Notch 1 I 32 2.18 (0.9–5.28) 0.076
II 67 0.76 (0.39–1.48) 0.41
III 165 1.31 (0.84–2.05) 0.24
Notch 2 I 32 10.5 (1.4–78.81) 0.0046
II 67 1.68 (0.87–3.21) 0.12
III 165 1.37 (0.92–2.05) 0.12
Notch 3 I 32 1.28 (0.54–3.03) 0.57
II 67 1.5 (0.76–2.97) 0.24
III 165 1.3 (0.84–2.03) 0.24
Notch 4 I 32 1.72 (0.69–4.27) 0.24
II 67 1.52 (0.79–2.94) 0.2
III 165 0.8 (0.53–1.2) 0.28
Open in a new tab

Table 3. Correlation of Notch receptor mRNA high expression with clinical stages of gastric cancer patients.

Notch receptors Clinical stages Cases HR 95% CI P value
Notch1 1 67 3.17 (0.9–11.19) 0.058
2 140 1.95 (1.04–3.64) 0.033
3 305 1.49 (1.07–2.06) 0.017
4 148 0.73 (0.49–1.07) 0.1
Notch2 1 67 2.1 (0.75–5.83) 0.15
2 140 2.26 (1.23–4.14) 0.0066
3 305 2.03 (1.46–2.82) 1.7e-05
4 148 1.33 (0.87–2.03) 0.19
Notch3 1 67 2.76 (0.79–9.71) 0.098
2 140 0.55 (0.28–1.08) 0.077
3 305 1.8 (1.26–2.57) 0.0011
4 148 1.4 (0.94–2.11) 0.1
Notch4 1 67 3.7 × 108 (0.0-inf) 0.0035
2 140 2.32 (1.26–4.25) 0.0052
3 305 1.83 (1.31–2.54) 0.00028
4 148 1.56 (0.97–2.51) 0.062
Open in a new tab

Table 4. Correlation of Notch receptor mRNA high expression with HER2 status of gastric cancer patients.

Notch receptors HER2 status Cases HR 95% CI P value
Notch1 Negative 532 1.32 (1.05–1.65) 0.016
Positive 344 1.58 (1.2–2.09) 0.0011
Notch2 Negative 532 1.53 (1.22–1.93) 0.00023
Positive 344 1.44 (1.07–1.96) 0.017
Notch3 Negative 532 1.57 (1.22–2.01) 0.00043
Positive 344 1.31 (0.98–1.76) 0.065
Notch4 Negative 532 2.03 (1.61–2.57) 1.7e-09
Positive 344 1.62 (1.25–2.1) 0.00025
Open in a new tab

Table 5. Correlation of Notch receptor mRNA high expression with different treatment of gastric cancer patients.

Notch receptors Treatment Cases HR 95% CI P value
Notch1 Surgery alone 380 1.4 (1.02–1.93) 0.037
5-FU based Adjuvant 153 1.53 (1.07–2.19) 0.019
Notch2 Surgery alone 380 1.34 (0.98–1.85) 0.068
5-FU based Adjuvant 153 0.61 (0.43–0.87) 0.0059
Notch3 Surgery alone 380 1.42 (1.00–2.02) 0.048
5-FU based Adjuvant 153 0.82 (0.56–1.21) 0.31
Surgery alone 380 2.12 (1.48–3.03) 2.7e-05
Notch4 5-FU based Adjuvant 153 1.22 (0.85–1.74) 0.27
Open in a new tab

Discussion

Among four Notch receptors and ligands, Notch1 is relatively the most studied member of Notch signaling in gastric carcinogenesis7,37,38,39. With the active form of Notch 1, the Notch 1 intracellular domain (NICD) was frequently expressed in gastric cancer cell lines, and the depletion of Notch 1 by Notch 1 siRNA led to growth inhibition of gastric cancer cells17,40. Down-regulation of Notch1 expression by gamma-secretase inhibition (N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester, DAPT) was also able to substantially inhibit migration, invasion, and proliferation, as well as epithelial-mesenchymal transition in gastric cancer cell lines41. Changes in the expression of the Notch1 intracellular domain (NICD) differentially expressed in gastric cancer, and the aberrant expression of Notch1 NICD is associated with an advanced tumor stage, tumor metastasis and overall patient survival42. Du et al.43 performed a meta-analysis and showed that the expression of Notch1 protein was significantly higher in tumor tissues of gastric cancer compared to normal tissues. Specifically, stratified analyses showed that significantly increased expression of Notch1 was associated with non-cardia location, >5 cm size, diffuse type, positive lymphovascular invasion and distal metastasis, indicating that Notch1 protein may be an oncogene. Recently, Bauer et al.44 reported that primarily resected patients with Notch1 protein-negative tumors demonstrated worse survival and high Notch1protein expression was associated with early-stage tumors and associated with significantly increased survival in this subgroup. Their results supported that Notch1 expression indicated good prognosis in gastric cancer patients. However, whether or not Notch1 mRNA has a prognostic role in gastric cancer patients remains elusive. In this report, Notch1′s high mRNA expression was found to be correlated to worsen OS for all gastric cancer patients followed for 20 years. Notch1′s high mRNA expression was also found to be correlated to worsen OS in intestinal type cancer patients, but not in diffuse type cancer patients.

Notch2 activation was observed in 10.0% (1 of 10) of noncancerous endoscopic mucosa, 71.4% (30 of 42) in premalignant lesions, and 97.3% (72 of 74) in gastric cancer tissues, demonstrating a correlation of Notch2 expression with both intestinal and diffuse gastric cancer formation45. Constitutive expression of Notch2 NICD promoted both cell proliferation and xenografted tumor growth of human gastric adenocarcinoma SC-M1 cells46. Immunohistochemical analysis demonstrated a chemotherapy-associated increase in the intensity of Notch2 staining, indicating a prominent role for Notch2 in chemotherapy resistance of gastric cancer47. Above results indicate that Notch2 seems to be a tumor oncogene in gastric carcinogenesis. Du et al.43 reported that the expression of Notch2 protein significantly was higher in tumor tissues of gastric cancer compared to normal tissues. However, Bauer et al.44 reported that higher Notch2 protein expression was associated with early-stage and intestinal-type tumors and with associated better survival in the subgroup of intestinal-type tumors. Their results support that Notch2 expression with early tumor stages suggest that Notch2 may act as a tumor suppressor in gastric cancer. However, there is no report about the prognostic significance of Notch2 mRNA expression in gastric cancer. In this report, Notch2′s high mRNA expression was found to be significantly correlated to worsen OS for all gastric cancer patients, as well as in intestinal type cancer patients and in diffuse type cancer patients.

The study about Notch3 in gastric cancer is limited43. The expression of Notch3 protein was observed to be associated with the intestinal/glandular differentiation of gastric carcinoma cells, suggesting a role as a possible favorable prognostic indicator48. In this report, our results show that Notch3′s high mRNA expression was significantly correlated to worsen OS for all gastric cancer patients, as well as in intestinal type cancer patients and diffuse type cancer patients.

Same as Notch3, the study about Notch4 in gastric cancer is also limited. In a recent report49, Notch4 activation was observed to promote gastric cancer growth in vitro and in vivo, while Notch4 inhibition using Notch4 siRNA had opposite effects. In addition, Notch4 activation induced expression and activation of Wnt1, β-catenin and downstream target genes, c-Myc and cyclin D1, in gastric cancer cells, while Notch4 inhibition had opposite effects. Wnt1 is one of WNT members that regulates various processes including tumor initiation, tumor growth, cell senescence, cell death, differentiation and metastasis50,51. β-catenin is the primary transducer of canonical WNT signals to the nucleus and is involved in the development and progression of a significant proportion of gastric cancer cases52,53. Activation of the cyclin D1 oncogene, often by amplification or rearrangement, is a central mediator in the transition from G1 to S phase and a major driver of multiple types of human tumors including gastric cancer54,55,56. These results indicate that Notch4 seems to be a tumor oncogene in gastric carcinogenesis. In this report, we observed that Notch4′s high mRNA expression was also found to be significantly correlated to worsen OS for all gastric cancer patients, intestinal type cancer patients, and diffuse type of cancer patients.

The HER2/neu proto-oncogene (also known as c-erbB-2) encodes a 185 kDa transmembrane glycoprotein receptor known as HER2/neu or p185,HER2 partial homology with EGFR. HER2/neu shares a receptor with intrinsic tyrosine kinase activity and has been implicated in cancer with special emphasis in breast cancer57,58. HER2 overexpression was detected in 6% to 35% of GC patients and led to the advent of targeted therapy with anti HER2 antibody like Trastusumab which has improved the overall survival59,60. In this study, we found that all the individual Notch receptors except Notch 3 are significantly associated with worsen OS in either HER2 negative or HER2 positive gastric cancer patients. Notch 3′s high mRNA expression is only significantly associated with worsen OS in HER2 negative gastric cancer patients.

The connection between Notch signaling and carcinogenesis, as well as its crosstalk with many oncogenic signaling pathways suggest that Notch signaling, especially some Notch receptors may be candidate for drug target of gastric cancer. A number of γ-secretase inhibitors were demonstrated to inhibit Notch activation and cell growth in gastric cancer cells41,45,61,62. The treatment combination of γ-secretase inhibitor and 5-FU was shown to be better than that with the single treatment in the inhibition of gastric cancer cell proliferation61. Therefore, Notch expression status could also impact the treatment efficiency of 5-FU based adjuvant therapy and/or prognosis of gastric cancer patients. In this study, we observed that Notch 1 mRNA high expression is associated with worsen OS in surgery alone gastric cancer patients and 5-FU based adjuvant gastric cancer patients. Notch 3 and Notch 4′s high mRNA expression is only associated with worsen OS in surgery alone for gastric cancer patients. Interestingly, Notch 2′s high mRNA expression is only associated with better OS in 5-FU based adjuvant gastric cancer patients.

In summary, by using the KM plotter database, we accessed the prognostic roles of four Notch receptors in gastric cancer patients through KM plotter, in which updated gene expression data and survival information included data from a total of 876 gastric cancer patients. All four Notch receptors’ high mRNA expression was found to be correlated to worsen overall survival (OS) for all gastric cancer patients followed for 20 years. We further accessed the prognostic roles of individual Notch receptors in different clinicopathological features including Lauren classification, pathological grades, clinical grades, HER2 status and different choices of treatments of gastric cancer patients. These results indicate that there are critical prognostic values of Notch 1–4 receptors in gastric cancer. This information will be useful for the better understanding of the heterogeneity and complexity in the molecular biology of gastric cancer and to develop tools to more accurately predict their prognosis.

Additional Information

How to cite this article: Wu, X. et al. Prognostic values of four Notch receptor mRNA expression in gastric cancer. Sci. Rep. 6, 28044; doi: 10.1038/srep28044 (2016).

Acknowledgments

This research was supported in part by National Science Foundation of China (81402523 to XW, 81201797 to GL), Jiangsu Province “Six adults just” high peak (2009-D-63 to GL), Youth Projects of Jiangsu Provincial Health Department (H201065 to GL), and the Natural Science Foundation of Jiangsu Province (BK2009445 to GL).

Footnotes

Author Contributions X.W., W.L. and G.L. participated in the design of the study and drafted the manuscript. X.W., W.L., Z.W., C.C., X.Y. and F.L. reviewed and extracted data. X.W., W.L., D.T., H.X. and Z.W. participated in the research of the study and performed the statistical analysis. All authors reviewed the manuscript.

References

  1. Jemal A. et al. Global cancer statistics. CA Cancer J Clin 61, 69–90 (2011). [DOI] [PubMed] [Google Scholar]
  2. Yang W., Raufi A. & Klempner S. J. Targeted therapy for gastric cancer: Molecular pathways and ongoing investigations. Biochim Biophys Acta 22, 00048–00041 (2014). [DOI] [PubMed] [Google Scholar]
  3. Oba K. et al. Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Eur J Cancer 49, 1565–1577 (2013). [DOI] [PubMed] [Google Scholar]
  4. Cao Y., DePinho R. A., Ernst M. & Vousden K. Cancer research: past, present and future. Nat Rev Cancer 11, 749–754, doi: nrc3138 (2011). [DOI] [PubMed] [Google Scholar]
  5. Lewis J. Notch signalling and the control of cell fate choices in vertebrates. Semin Cell Dev Biol 9, 583–589, doi: S1084-9521(98)90266-X (1998). [DOI] [PubMed] [Google Scholar]
  6. Simpson P. Developmental genetics. The Notch connection. Nature 375, 736–737, doi: 10.1038/375736a0[doi] (1995). [DOI] [PubMed] [Google Scholar]
  7. Katoh M. Notch signaling in gastrointestinal tract (review). Int J Oncol 30, 247–251 (2007). [PubMed] [Google Scholar]
  8. Kopan R. & Ilagan M. X. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137, 216–233, doi: S0092-8674(09)00382-1 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Miele L. Notch signaling. Clin Cancer Res 12, 1074–1079, doi: 12/4/1074 (2006). [DOI] [PubMed] [Google Scholar]
  10. Miele L., Miao H. & Nickoloff B. J. NOTCH signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets 6, 313–323 (2006). [DOI] [PubMed] [Google Scholar]
  11. Alketbi A. & Attoub S. Notch Signaling in Cancer: Rationale and Strategies for Targeting. Curr Cancer Drug Targets 15, 364–374, doi: CCDT-EPUB-68718 (2015). [DOI] [PubMed] [Google Scholar]
  12. Chiaramonte R. et al. Notch pathway promotes ovarian cancer growth and migration via CXCR4/SDF1alpha chemokine system. Int J Biochem Cell Biol 66, 134–140, doi: S1357-2725(15)00200-9 (2015). [DOI] [PubMed] [Google Scholar]
  13. Demitrack E. S. et al. Notch signaling regulates gastric antral LGR5 stem cell function. EMBO J 34, 2522–2536, doi: embj.201490583 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kim S. J. et al. Activation of nuclear PTEN by inhibition of Notch signaling induces G2/M cell cycle arrest in gastric cancer. Oncogene 30, 80, doi: onc201580 (2015). [DOI] [PubMed] [Google Scholar]
  15. Yang G., Gong Y., Wang Q., Wang Y. & Zhang X. The role of miR-100-mediated Notch pathway in apoptosis of gastric tumor cells. Cell Signal 27, 1087–1101, doi: S0898-6568(15)00059-5 (2015). [DOI] [PubMed] [Google Scholar]
  16. Yang Z. et al. Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop. Oncotarget 6, 5072–5087, doi: 3241 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Yao J. & Qian C. Over-activated Notch-1 protects gastric carcinoma BGC-823 cells from TNFalpha-induced apoptosis. Dig Liver Dis 41, 867–874, doi: S1590-8658(09)00147-9 (2009). [DOI] [PubMed] [Google Scholar]
  18. Yan B. et al. Xiaotan Sanjie decoction attenuates tumor angiogenesis by manipulating Notch-1-regulated proliferation of gastric cancer stem-like cells. World J Gastroenterol 20, 13105–13118, doi: 10.3748/wjg.v20.i36.13105 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Gyorffy B., Surowiak P., Budczies J. & Lanczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. Plos one 8, e82241, doi: 10.1371/journal.pone.0082241 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. You Q., Guo H. & Xu D. Distinct prognostic values and potential drug targets of ALDH1 isoenzymes in non-small-cell lung cancer. Drug Des Devel Ther 9, 5087–5097, doi: 10.2147/DDDT.S87197 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Dotsch M. M. et al. Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients’ outcome. Epigenetics 10, 903–912, doi: 10.1080/15592294.2015.1078049 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ortega C. E., Seidner Y. & Dominguez I. Mining CK2 in cancer. Plos one 9, e115609, doi: 10.1371/journal.pone.0115609 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Liu M., Wang G., Gomez-Fernandez C. R. & Guo S. GREB1 Functions as a Growth Promoter and Is Modulated by IL6/STAT3 in Breast Cancer. Plos one 7, e46410 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  24. Tilghman S. L. et al. Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness. Mol Cell Proteomics 12, 2440–2455, doi: M112.023861 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Zhou C. et al. Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Res 14, R45, doi: bcr3144 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Maciejczyk A. et al. Elevated BUBR1 expression is associated with poor survival in early breast cancer patients: 15-year follow-up analysis. J Histochem Cytochem 61, 330–339, doi: 0022155413480148 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Maciejczyk A. et al. Elevated nuclear S100P expression is associated with poor survival in early breast cancer patients. Histol Histopathol 28, 513–524, doi: HH-11-254 (2013). [DOI] [PubMed] [Google Scholar]
  28. Maciejczyk A. et al. ABCC2 (MRP2, cMOAT) localized in the nuclear envelope of breast carcinoma cells correlates with poor clinical outcome. Pathol Oncol Res 18, 331–342, doi: 10.1007/s12253-011-9449-9 (2012). [DOI] [PubMed] [Google Scholar]
  29. Adam M. A. New prognostic factors in breast cancer. Adv Clin Exp Med 22, 5–15 (2013). [PubMed] [Google Scholar]
  30. Ivanova L. et al. Prognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast cancer cells. Cancer Chemother Pharmacol 75, 235–246, doi: 10.1007/s00280-014-2635-1 (2015). [DOI] [PubMed] [Google Scholar]
  31. Wu S. et al. Distinct prognostic values of ALDH1 isoenzymes in breast cancer. Tumour Biol 13, 13, doi: 10.1007/s13277-014-2852-6 (2015). [DOI] [PubMed] [Google Scholar]
  32. Hong C. Q. et al. Elevated C1orf63 expression is correlated with CDK10 and predicts better outcome for advanced breast cancers: a retrospective study. BMC Cancer 15, 548, doi: 10.1186/s12885-015-1569-2 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Kamieniak M. M. et al. Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients. Mol Oncol 9, 422–436, doi: S1574-7891(14)00234-8 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Gayarre J. et al. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients. J Gynecol Oncol 12, 12, doi: 26.e36 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Gyorffy B. et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123, 725–731, doi: 10.1007/s10549-009-0674-9 (2010). [DOI] [PubMed] [Google Scholar]
  36. Gyorffy B., Lanczky A. & Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer 19, 197–208, doi: ERC-11-0329 (2012). [DOI] [PubMed] [Google Scholar]
  37. Chen D. H., Yu J. W. & Jiang B. J. Contactin 1: A potential therapeutic target and biomarker in gastric cancer. World J Gastroenterol 21, 9707–9716, doi: 10.3748/wjg.v21.i33.9707 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Han M. E. & Oh S. O. Gastric stem cells and gastric cancer stem cells. Anat Cell Biol 46, 8–18, doi: 10.5115/acb.2013.46.1.8 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Piazzi G., Bazzoli F. & Ricciardiello L. Epigenetic silencing of Notch signaling in gastrointestinal cancers. Cell Cycle 11, 4323–4327, doi: 22388 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Wei G. et al. Notch1 silencing inhibits proliferation and invasion in SGC7901 gastric cancer cells. Mol Med Rep 9, 1153–1158, doi: 10.3892/mmr.2014.1920 (2014). [DOI] [PubMed] [Google Scholar]
  41. Li L. C., Peng Y., Liu Y. M., Wang L. L. & Wu X. L. Gastric cancer cell growth and epithelial-mesenchymal transition are inhibited by gamma-secretase inhibitor DAPT. Oncol Lett 7, 2160–2164, doi: 10.3892/ol.2014.1980 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Luo D. H. et al. Differential expression of Notch1 intracellular domain and p21 proteins, and their clinical significance in gastric cancer. Oncol Lett 7, 471–478, doi: 10.3892/ol.2013.1751 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Du X. et al. Role of Notch signaling pathway in gastric cancer: a meta-analysis of the literature. World J Gastroenterol 20, 9191–9199, doi: 10.3748/wjg.v20.i27.9191 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Bauer L. et al. Clinical Significance of NOTCH1 and NOTCH2 Expression in Gastric Carcinomas: An Immunohistochemical Study. Front Oncol 5, 94, doi: 10.3389/fonc.2015.00094 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Sun Y. et al. Differential Notch1 and Notch2 expression and frequent activation of Notch signaling in gastric cancers. Arch Pathol Lab Med 135, 451–458, doi: 10.1043/2009-0665-OA.1 (2011). [DOI] [PubMed] [Google Scholar]
  46. Tseng Y. C. et al. Notch2-induced COX-2 expression enhancing gastric cancer progression. Mol Carcinog 51, 939–951, doi: 10.1002/mc.20865 (2012). [DOI] [PubMed] [Google Scholar]
  47. Bauer L. et al. Expression profiling of stem cell-related genes in neoadjuvant-treated gastric cancer: a NOTCH2, GSK3B and beta-catenin gene signature predicts survival. Plos one 7, e44566, doi: 10.1371/journal.pone.0044566 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Kang H. et al. Notch3 and Jagged2 contribute to gastric cancer development and to glandular differentiation associated with MUC2 and MUC5AC expression. Histopathology 61, 576–586, doi: 10.1111/j.1365-2559.2012.04274.x (2012). [DOI] [PubMed] [Google Scholar]
  49. Qian C. et al. Notch4 promotes gastric cancer growth through activation of Wnt1/beta-catenin signaling. Mol Cell Biochem 401, 165–174, doi: 10.1007/s11010-014-2304-z (2015). [DOI] [PubMed] [Google Scholar]
  50. Anastas J. N. & Moon R. T. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 13, 11–26, doi: nrc3419 (2013). [DOI] [PubMed] [Google Scholar]
  51. You L. et al. Wnt-1 signal as a potential cancer therapeutic target. Drug News Perspect 19, 27–31, doi: 965871 (2006). [DOI] [PubMed] [Google Scholar]
  52. McCrea P. D. & Gottardi C. J. Beyond beta-catenin: prospects for a larger catenin network in the nucleus. Nat Rev Mol Cell Biol 17, 55–64, doi: nrm.2015.3 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Chiurillo M. A. Role of the Wnt/beta-catenin pathway in gastric cancer: An in-depth literature review. World J Exp Med 5, 84–102, doi: 10.5493/wjem.v5.i2.84 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Casimiro M. C., Velasco-Velazquez M., Aguirre-Alvarado C. & Pestell R. G. Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present. Expert Opin Investig Drugs 23, 295–304, doi: 10.1517/13543784.2014.867017 (2014). [DOI] [PubMed] [Google Scholar]
  55. Feakins R. M., Nickols C. D., Bidd H. & Walton S. J. Abnormal expression of pRb, p16, and cyclin D1 in gastric adenocarcinoma and its lymph node metastases: relationship with pathological features and survival. Hum Pathol 34, 1276–1282, doi: S0046817703004726 (2003). [DOI] [PubMed] [Google Scholar]
  56. Pradeep A. et al. Gastrin-mediated activation of cyclin D1 transcription involves beta-catenin and CREB pathways in gastric cancer cells. Oncogene 23, 3689–3699, doi: 10.1038/sj.onc.1207454 (2004). [DOI] [PubMed] [Google Scholar]
  57. Tai W., Mahato R. & Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release, doi: S0168-3659(10)00263-4 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Tzahar E. & Yarden Y. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim Biophys Acta 1377, M25–37, doi: S0304-419X(97)00032-2 (1998). [DOI] [PubMed] [Google Scholar]
  59. Ruschoff J. et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 25, 637–650, doi: modpathol2011198 (2012). [DOI] [PubMed] [Google Scholar]
  60. Rajagopal I., Niveditha S. R., Sahadev R., Nagappa P. K. & Rajendra S. G. HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas. J Clin Diagn Res 9, EC06–10, doi: 10.7860/JCDR/2015/12581.5630 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Yao J. et al. Combination treatment of PD98059 and DAPT in gastric cancer through induction of apoptosis and downregulation of WNT/beta-catenin. Cancer Biol Ther 14, 833–839, doi: 25332 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Hong K. J., Wu D. C., Cheng K. H., Chen L. T. & Hung W. C. RECK inhibits stemness gene expression and tumorigenicity of gastric cancer cells by suppressing ADAM-mediated Notch1 activation. J Cell Physiol 229, 191–201, doi: 10.1002/jcp.24434 (2014). [DOI] [PubMed] [Google Scholar]

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES